ApoB is the most accurate predictor of cardiovascular disease risk available without imaging. This guide covers every evidence-based intervention — dietary, lifestyle, and pharmacological — ranked by effect size, with realistic expectations for how much each one moves the needle.
Most people have had their cholesterol checked. Almost none have had their ApoB checked. That’s a problem, because ApoB is a fundamentally different measurement — and a more accurate one.
LDL cholesterol measures the amount of cholesterol carried inside LDL particles. ApoB counts the particles themselves. Every atherogenic lipoprotein — LDL, VLDL, IDL, Lp(a) — carries exactly one ApoB protein. So ApoB is a direct census of the particles that drive plaque formation and atherosclerosis.
The 2024 National Lipid Association Expert Consensus confirmed what cardiovascular researchers have argued for years: ApoB and non-HDL-C stratify cardiovascular risk more accurately than LDL-C, particularly when the two are discordant. Discordance — where LDL-C looks normal but ApoB is elevated — is common in people with insulin resistance, metabolic syndrome, or low triglycerides. In those cases, LDL-C is systematically misleading, and ApoB is the signal that matters.
The target most longevity-focused clinicians aim for is ApoB below 90 mg/dL at minimum, with a more aggressive target of below 60 to 70 mg/dL for anyone with additional cardiovascular risk factors. If you don’t know your ApoB, that’s the starting point.
Below 90 mg/dL is the desirable threshold for low cardiovascular risk. Below 70 mg/dL is the target for high-risk individuals. For longevity optimization with no other risk factors, many clinicians target below 80 mg/dL. The 2024 NLA consensus proposes thresholds of 90, 70, and 60 mg/dL for borderline-to-intermediate, high, and very high ASCVD risk respectively.
Here is every evidence-based intervention for lowering ApoB, with realistic effect size estimates from clinical research. These are not strictly additive — the total reduction from multiple simultaneous changes will vary based on baseline ApoB, genetics, and adherence — but the ranking reflects relative leverage.
| Intervention | Estimated ApoB reduction | Evidence | Impact |
|---|---|---|---|
| Statin therapy (high-intensity) | 35–55% | Extensive RCT data | High |
| PCSK9 inhibitors (alirocumab, evolocumab) | 50–60% on top of statin | Multiple large RCTs | High |
| Statin + ezetimibe combination | Additional 15–20% vs. statin alone | Strong RCT evidence | High |
| Plant sterols/stanols (2g/day) | 8–10% | Multiple RCTs | High |
| Reduce saturated fat (<7% of calories) | 5–10% | Strong evidence | High |
| Increase soluble fiber (25–30g/day) | 5–10% | Strong evidence | High |
| Weight loss (per 10% body weight) | ~10% | Consistent across studies | High |
| Regular aerobic exercise (150+ min/week) | 3–8% | Moderate RCT evidence | Medium |
| Switch from unfiltered to filtered coffee | 3–6% | Moderate evidence | Medium |
| Replace refined grains with whole grains | 3–5% | Moderate evidence | Medium |
| Omega-3 supplementation (2–4g EPA+DHA/day) | 2–5% | Moderate evidence | Medium |
| Mediterranean dietary pattern | 5–15% (combined effect) | Strong observational + RCT | Medium |
| Smoking cessation | Indirect — reduces VLDL and improves lipid clearance | Strong evidence | Medium |
| Reduce alcohol intake | 2–4% for heavy drinkers | Moderate evidence | Low–Med |
| Sleep optimization (7–9 hours) | Indirect — reduces metabolic dysfunction | Observational | Low |
| Stress reduction | Indirect via cortisol and metabolic pathways | Observational | Low |
Saturated fat is the dominant dietary driver of elevated ApoB. It down-regulates hepatic LDL receptor expression, reducing the liver’s ability to clear ApoB-containing particles from circulation. The NIH’s Therapeutic Lifestyle Changes program and the 2020–2025 Dietary Guidelines for Americans both recommend limiting saturated fat to less than 7 to 10 percent of daily calories for cardiovascular risk reduction.
On a 2,000-calorie diet, that’s less than 16 to 22 grams of saturated fat per day. The primary sources in a Western diet: red meat (especially processed), full-fat dairy (butter, hard cheeses, cream), tropical oils (coconut, palm), and ultra-processed foods. A single tablespoon of butter contains approximately 7g of saturated fat.
Critically: what you replace saturated fat with matters as much as the reduction itself. A 2024 clinical trial found that a low-carb diet high in saturated fat raised ApoB compared to a standard diet. Replacing saturated fat with refined carbohydrates produces no cardiovascular benefit. The evidence-backed replacement is unsaturated fat — monounsaturated (olive oil, avocados, almonds) and polyunsaturated (fatty fish, walnuts, flaxseed).
Soluble fiber lowers ApoB through two mechanisms: it binds bile acids in the gut, forcing the liver to convert more cholesterol into bile acids (drawing down circulating cholesterol), and it reduces post-meal glucose spikes that drive VLDL production. Psyllium husk, oats, legumes, apples, and flaxseed are the most practical high-fiber sources.
The therapeutic target is 25 to 30 grams of total fiber per day, with at least 10 to 15 grams from soluble sources. Most adults consuming a Western diet get roughly 10 to 15 grams total. Doubling fiber intake consistently is a meaningful intervention — not a marginal one.
Plant sterols and stanols competitively inhibit cholesterol absorption in the small intestine. At 2 grams per day — the dose used in clinical trials — they reduce LDL-C and ApoB by 8 to 10%. This is a well-established, dose-dependent effect confirmed across multiple randomized controlled trials.
Plant sterol supplements are available over the counter. The most practical approach is 1 gram with two meals. Note: there is a small subset of people with mutations in the ABCG5/8 genes (sitosterolemia) who should exercise caution — plant sterols may increase their cardiovascular risk rather than reduce it.
Unfiltered coffee — French press, espresso, Turkish coffee — contains diterpenes (cafestol and kahweol) that raise ApoB and LDL-C by inhibiting bile acid synthesis. Switching from unfiltered to filtered coffee removes these compounds and produces a 3 to 6% reduction in ApoB for regular consumers. If you drink two or more cups of French press daily, this is a low-effort, meaningful swap.
Low-carbohydrate diets can lower ApoB when carbohydrates are replaced with unsaturated fats. But when carbohydrates are replaced with saturated fat — as is common in practice — ApoB often rises. If you follow a low-carb or ketogenic diet and have elevated ApoB, the source of dietary fat is the critical variable to examine. Lean meats, olive oil, nuts, and avocados are compatible with ApoB reduction. Butter, bacon, and full-fat dairy in large quantities are not.
Regular aerobic exercise lowers ApoB through improved lipoprotein lipase activity, enhanced hepatic clearance of ApoB-containing particles, and reduced VLDL production. The effect size is modest (3 to 8%) but consistent across studies, and exercise operates synergistically with dietary interventions.
High-intensity interval training shows the strongest individual effect on ApoB in clinical trials, though the studies are small. Zone 2 aerobic exercise performed consistently — 150 or more minutes per week at a conversational pace — also produces measurable reductions and improves insulin sensitivity, which further reduces VLDL-ApoB output from the liver.
Excess body fat, particularly visceral adiposity, drives elevated VLDL production and impairs lipoprotein clearance. Weight loss reduces ApoB roughly proportionally: approximately 1% reduction in ApoB per 1% reduction in body weight in people who are overweight. A 10% reduction in body weight typically produces a ~10% reduction in ApoB.
The evidence for sleep and stress management acting directly on ApoB is primarily observational. Both operate through the same downstream pathway: chronic sleep deprivation and elevated cortisol increase insulin resistance, which drives VLDL overproduction. Optimizing sleep (7 to 9 hours) and managing chronic stress removes a metabolic headwind that can blunt the effect of dietary and exercise interventions.
Upload your lab results and get a longevity-optimized analysis — ApoB, LDL-C, triglycerides, fasting insulin, and more — scored against optimal ranges and prioritized for action.
For a meaningful subset of people — particularly those with familial hypercholesterolemia or strong genetic predisposition — lifestyle interventions alone will not lower ApoB to target. Genetic variants that reduce hepatic LDL receptor expression or increase hepatic ApoB production are common and not corrected by diet and exercise.
The clinical signal to consider pharmacotherapy: ApoB remains above 90 mg/dL after 3 to 6 months of consistent dietary and exercise intervention. The standard pharmacological options:
ApoB is not included in standard lipid panels. You need to order it explicitly. It’s available as a single-marker add-on through Ulta Lab Tests for around $20–30, or included in comprehensive panels through Superpower. See the ordering options below.
ApoB is a standard blood test, but it’s almost never included in routine lipid panels. You need to order it separately, or use a service that includes it by default.